Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The disclosure states that Panmure Gordon (UK) Limited, as an exempt principal trader, has made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares. The disclosure shows that Panmure Gordon (UK) Limited has purchased 0 securities and sold 1,020,087 securities at a highest price per unit of 0.0285 and a lowest price per unit of 0.0279.

The disclosure does not mention any cash-settled derivative transactions or stock-settled derivative transactions related to Allergy Therapeutics' securities. It also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities between Panmure Gordon (UK) Limited and any other party.

The disclosure was made on September 18, 2023, and the contact person for further information is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969. The disclosure also mentions that public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service, and the Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.